Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 11Genitourinary 8Gastrointestinal 8Head & Neck 5Breast 4Gynecologic 3Tumor-Agnostic 2Other hematologic neoplasm 2Dermatologic 2CNS 2Plasma cell 1Other solid neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

venetoclax 138Cytarabine 108Cyclophosphamide 107Specimen Handling 98fludarabine 88Azacitidine 87Biopsy 74Rituximab 45Methotrexate 43Daunorubicin 42fludarabine phosphate 40Magnetic Resonance Spectroscopy 38Vincristine 36Dexamethasone 36blinatumomab 32Injections 32Decitabine 32Granulocyte Colony-Stimulating Factor 29Whole-Body Irradiation 28Mycophenolic Acid 28Idarubicin 27ibrutinib 26Tacrolimus 26Prednisone 26Etoposide 26Doxorubicin 25Busulfan 25acalabrutinib 24Melphalan 24Calcium Dobesilate 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observation × Other hematologic neoplasm × 90 days × Clear all
NCT03737981 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
465 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02275533 2026-05-28

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
82 enrolled 13 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡